Loss of epigenetic kruppel-like factor 4 histone deacetylase (KLF-4-HDAC)-mediated transcriptional suppression is crucial in increasing vascular endothelial growth factor (VEGF) expression in breast cancer

Journal of Biological Chemistry

Volumn 288, Issue 38, 2013, Pages 27232-27242

  Ray, Alpana ^a   Alalem, Mohamed ^a   Ray, Bimal K ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER CELLS; HISTONE DEACETYLASES; KRUPPEL-LIKE FACTORS; PATHOLOGICAL CONDITIONS; TRANSCRIPTIONAL ACTIVATIONS; TRANSCRIPTIONAL REPRESSION; TRANSCRIPTIONAL REPRESSORS; VASCULAR ENDOTHELIAL GROWTH FACTOR;

CELL ENGINEERING; DISEASES; MOLECULAR BIOLOGY; TRANSCRIPTION FACTORS;

ENDOTHELIAL CELLS;

CHLORAMPHENICOL ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 8; KRUPPEL LIKE FACTOR 4; SERUM AMYLOID A ACTIVATING FACTOR 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BREAST CANCER; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER CELL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; EPIGENETIC REPRESSION; EPIGENETICS; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MCF 10A CELL; MDA MB 231 CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; RNA ISOLATION; TRANSCRIPTION INITIATION;

ANGIOGENESIS; BREAST CANCER; DNA-PROTEIN INTERACTION; GENE REGULATION; TRANSCRIPTION FACTORS;

BREAST NEOPLASMS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE 2; HISTONE DEACETYLASES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROMOTER REGIONS, GENETIC; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84884569020     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.481184     Document Type: Article

References (72)

1. Folkman, J., Merler, E., Abernathy, C., and Williams, G. (1971) Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med. 133, 275-288
2. Engels, K., Fox, S. B., Whitehouse, R. M., Gatter, K. C., and Harris, A. L. (1997) Distinct angiogenic patterns are associated with high-grade in situ ductal carcinomas of the breast. J. Pathol. 181, 207-212
3. Ferrara, N. (1995) The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res. Treat. 36, 127-137
4. Ferrara, N. (2002) Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol. 29, 10-14
5. Yoshiji, H., Gomez, D. E., Shibuya, M., and Thorgeirsson, U. P. (1996) Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res. 56, 2013-2016
6. Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Guidi, A. J., Dvorak, H. F., Senger, D. R., Connolly, J. L., and Schnitt, S. J. (1995) Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum. Pathol. 26, 86-91
7. Van der Auwera, I., Van Laere, S. J., Van Den Eynden, G. G., Benoy, I., Van Dam, P., Colpaert, C. G., Fox, S. B., Turley, H., Harris, A. L., Van Marck, E. A., Vermeulen, P. B., and Dirix, L. Y. (2004) Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin. Cancer Res. 10, 7965-7971
8. Jacobs, E. J., Feigelson, H. S., Bain, E. B., Brady, K. A., Rodriguez, C., Stevens, V. L., Patel, A. V., Thun, M. J., and Calle, E. E. (2006) Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res. 8, R22
9. Ray, A., Dhar, S., and Ray, B. K. (2011) Control of VEGF expression in triple-negative breast carcinoma cells by suppression of SAF-1 transcription factor activity. Mol. Cancer Res. 9, 1030-1041
10. Shields, J. M., Christy, R. J., and Yang, V. W. (1996) Identification and characterization of a gene encoding a gut-enriched Kruppel-like factor expressed during growth arrest. J. Biol. Chem. 271, 20009-20017
11. McConnell, B. B., and Yang, V. W. (2010) Mammalian Kruppel-like factors in health and diseases. Physiol. Rev. 90, 1337-1381
12. Atkins, G. B., and Jain, M. K. (2007) Role of Kruppel-like transcription factors in endothelial biology. Circ. Res. 100, 1686-1695
13. Allred, D. C., Clark, G. M., Elledge, R., Fuqua, S. A., Brown, R. W., Chamness, G. C., Osborne, C. K., and McGuire, W. L. (1993) Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J. Natl. Cancer Inst. 85, 200-206
14. Bouras, T., Southey, M. C., and Venter, D. J. (2001) Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. Cancer Res. 61, 903-907
15. Wang, L., Hoque, A., Luo, R. Z., Yuan, J., Lu, Z., Nishimoto, A., Liu, J., Sahin, A. A., Lippman, S. M., Bast, R. C., Jr., and Yu, Y. (2003) Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer. Clin. Cancer Res. 9, 3660-3666
16. Ray, B. K., Shakya, A., and Ray, A. (2007) Vascular endothelial growth factor expression in arthritic joint is regulated by SAF-1 transcription factor. J. Immunol. 178, 1774-1782
17. Kumar, D., Ray, A., and Ray, B. K. (2009) Transcriptional synergy mediated by SAF-1 and AP-1: critical role of N-terminal polyalanine and two zinc finger domains of SAF-1. J. Biol. Chem. 284, 1853-1862
18. Thomas-Chollier, M., Sand, O., Turatsinze, J. V., Janky, R., Defrance, M., Vervisch, E., Brohée, S., and Van Helden, J. (2008) RSAT: regulatory sequence analysis tools. Nucleic Acids Res. 36, W119-W127
19. Finkenzeller, G., Sparacio, A., Technau, A., Marmé, D., and Siemeister, G. (1997) Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression. Oncogene 15, 669-676
20. Stoner, M., Wormke, M., Saville, B., Samudio, I., Qin, C., Abdelrahim, M., and Safe, S. (2004) Estrogen regulation of vascular endothelial growth factor gene expression in ZR-75 breast cancer cells through interaction of estrogen receptor α and SP proteins. Oncogene 23, 1052-1063
21. Abdelrahim, M., Smith, R., 3rd, Burghardt, R., and Safe, S. (2004) Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res. 64, 6740-6749
22. Deacon, K., Onion, D., Kumari, R., Watson, S. A., and Knox, A. J. (2012) Elevated SP-1 transcription factor expression and activity drives basal and hypoxia-induced vascular endothelial growth factor (VEGF) expression in non-small cell lung cancer. J. Biol. Chem. 287, 39967-39981
23. Song, Y., Wu, J., Oyesanya, R. A., Lee, Z., Mukherjee, A., and Fang, X. (2009) Sp-1 and c-Myc mediate lysophosphatidic acid-induced expression of vascular endothelial growth factor in ovarian cancer cells via a hypoxiainducible factor-1-independent mechanism. Clin. Cancer Res. 15, 492-501
24. Stoner, M., Wang, F., Wormke, M., Nguyen, T., Samudio, I., Vyhlidal, C., Marme, D., Finkenzeller, G., and Safe, S. (2000) Inhibition of vascular endothelial growth factor expression in HEC1A endometrial cancer cells through interactions of estrogen receptor α and Sp3 proteins. J. Biol. Chem. 275, 22769-22779
25. Ray, A., Schatten, H., and Ray, B. K. (1999) Activation of Sp1 and its functional co-operation with serum amyloid A-activating sequence binding factor in synoviocyte cells trigger synergistic action of interleukin-1 and interleukin-6 in serum amyloid A gene expression. J. Biol. Chem. 274, 4300-4308
26. Song, J., Ugai, H., Nakata-Tsutsui, H., Kishikawa, S., Suzuki, E., Murata, T., and Yokoyama, K. K. (2003) Transcriptional regulation by zinc-finger proteins Sp1 and MAZ involves interactions with the same cis-elements. Int. J. Mol. Med. 11, 547-553
27. Evans, P. M., Zhang, W., Chen, X., Yang, J., Bhakat, K. K., and Liu, C. (2007) Kruppel-like factor 4 is acetylated by p300 and regulates gene transcription via modulation of histone acetylation. J. Biol. Chem. 282, 33994-34002
28. Wei, X., Xu, H., and Kufe, D. (2007) Human mucin 1 oncoprotein represses transcription of the p53 tumor suppressor gene. Cancer Res. 67, 1853-1858
29. Yoon, H. S., and Yang, V. W. (2004) Requirement of Kruppel-like factor 4 in preventing entry into mitosis following DNA damage. J. Biol. Chem. 279, 5035-5041
30. Ray, A., and Ray, B. K. (1998) Isolation and functional characterization of cDNA of serum amyloid A-activating factor that binds to the serum amyloid A promoter. Mol. Cell. Biol. 18, 7327-7335
31. Ray, B. K., and Ray, A. (1997) Involvement of an SAF-like transcription factor in the activation of serum amyloid A gene in monocyte/macrophage cells by lipopolysaccharide. Biochemistry 36, 4662-4668
32. Ray, A., and Ray, B. K. (1996) A novel cis-acting element is essential for cytokine-mediated transcriptional induction of the serum amyloid A gene in nonhepatic cells. Mol. Cell. Biol. 16, 1584-1594
33. Ray, B. K., Chatterjee, S., and Ray, A. (1999) Mechanism of minimally modified LDL-mediated induction of serum amyloidAgene in monocyte/macrophage cells. DNA Cell Biol. 18, 65-73
34. Ray, A., Kumar, D., and Ray, B. K. (2002) Promoter-binding activity of inflammation-responsive transcription factor SAF is regulated by cyclic AMP signaling pathway. DNA Cell Biol. 21, 31-40
35. Ray, A., Fields, A. P., and Ray, B. K. (2000) Activation of transcription factor SAF involves its phosphorylation by protein kinase C. J. Biol. Chem. 275, 39727-39733
36. Ray, A., Yu, G. Y., and Ray, B. K. (2002) Cytokine-responsive induction of SAF-1 activity is mediated by a mitogen-activated protein kinase signaling pathway. Mol. Cell. Biol. 22, 1027-1035
37. Ray, A., Ray, P., Guthrie, N., Shakya, A., Kumar, D., and Ray, B. K. (2003) Protein kinase A signaling pathway regulates transcriptional activity of SAF-1 by unmasking its DNA-binding domains. J. Biol. Chem. 278, 22586-22595
38. Tsutsui, H., Geltinger, C., Murata, T., Itakura, K., Wada, T., Handa, H., and Yokoyama, K. K. (1999) The DNA-binding and transcriptional activities of MAZ, a Myc-associated zinc finger protein, are regulated by casein kinase II. Biochem. Biophys. Res. Commun. 262, 198-205
39. Hamik, A., Lin, Z., Kumar, A., Balcells, M., Sinha, S., Katz, J., Feinberg, M. W., Gerzsten, R. E., Edelman, E. R., and Jain, M. K. (2007) Kruppel-like factor 4 regulates endothelial inflammation. J. Biol. Chem. 282, 13769-13779
40. Owens, G. K., Kumar, M. S., and Wamhoff, B. R. (2004) Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol. Rev. 84, 767-801
41. Zhang, W., Geiman, D. E., Shields, J. M., Dang, D. T., Mahatan, C. S., Kaestner, K. H., Biggs, J. R., Kraft, A. S., and Yang, V. W. (2000) The gut-enriched Kruppel-like factor (Kruppel-like factor 4) mediates the transactivating effect of p53 on the p21WAF1/Cip1 promoter. J. Biol. Chem. 275, 18391-18398
42. Wei, D., Kanai, M., Huang, S., and Xie, K. (2006) Emerging role of KLF4 in human gastrointestinal cancer. Carcinogenesis 27, 23-31
43. Kanai, M., Wei, D., Li, Q., Jia, Z., Ajani, J., Le, X., Yao, J., and Xie, K. (2006) Loss of Kruppel-like factor 4 expression contributes to Sp1 overexpression and human gastric cancer development and progression. Clin. Cancer Res. 12, 6395-6402
44. Li, J., Zheng, H., Yu, F., Yu, T., Liu, C., Huang, S., Wang, T. C., and Ai, W. (2012) Deficiency of the Kruppel-like factor KLF4 correlates with increased cell proliferation and enhanced skin tumorigenesis. Carcinogenesis 33, 1239-1246
45. Yori, J. L., Seachrist, D. D., Johnson, E., Lozada, K. L., Abdul-Karim, F. W., Chodosh, L. A., Schiemann, W. P., and Keri, R. A. (2011) Kruppel-like factor 4 inhibits tumorigenic progression and metastasis in a mouse model of breast cancer. Neoplasia 13, 601-610
46. Ai, W., Liu, Y., Langlois, M., and Wang, T. C. (2004) Kruppel-like factor 4 (KLF4) represses histidine decarboxylase gene expression through an upstream Sp1 site and downstream gastrin responsive elements. J. Biol. Chem. 279, 8684-8693;
47. Correction (2004) J. Biol. Chem. 279, 27830
48. Wade, P. A. (2001) Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Hum. Mol. Genet. 10, 693-698
49. Wolffe, A. P. (1996) Histone deacetylase: a regulator of transcription. Science 272, 371-372
50. Burke, L. J., and Baniahmad, A. (2000) Co-repressors 2000. FASEB J. 14, 1876-1888
51. Marks, P. A., Richon, V. M., Breslow, R., and Rifkind, R. A. (2001) Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 13, 477-483
52. Thiagalingam, S., Cheng, K.-H., Lee, H. J., Mineva, N., Thiagalingam, A., and Ponte, J. F. (2003) Histone deacetylases: unique players in shaping the epigenetic histone code. Ann. N. Y. Acad. Sci. 983, 84-100
53. Kee, H. J., and Kook, H. (2009) Kruppel-like factor 4 mediates histone deacetylase inhibitor-induced prevention of cardiac hypertrophy. J. Mol. Cell. Cardiol. 47, 770-780
54. Bergers, G., and Benjamin, L. E. (2003) Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3, 401-410
55. Baeriswyl, V., and Christofori, G. (2009) The angiogenic switch in carcinogenesis. Semin. Cancer Biol. 19, 329-337
56. Hanahan, D., and Folkman, J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364
57. Yu, T., Chen, X., Zhang, W., Li, J., Xu, R., Wang, T. C., Ai, W., and Liu, C. (2012) Kruppel-like factor 4 regulates intestinal epithelial cell morphology and polarity. PLoS ONE 7, e32492
58. Wang, N., Liu, Z.-H., Ding, F., Wang, X.-Q., Zhou, C.-N., and Wu, M. (2002) Down-regulation of gut-enriched Kruppel-like factor expression in esophageal cancer. World J. Gastroenterol. 8, 966-970
59. Ohnishi, S., Ohnami, S., Laub, F., Aoki, K., Suzuki, K., Kanai, Y., Haga, K., Asaka, M., Ramirez, F., and Yoshida, T. (2003) Downregulation and growth inhibitory effect of epithelial-type Kruppel-like transcription factor KLF4, but not KLF5, in bladder cancer. Biochem. Biophys. Res. Commun. 308, 251-256
60. Bianchi, F., Hu, J., Pelosi, G., Cirincione, R., Ferguson, M., Ratcliffe, C., Di Fiore, P. P., Gatter, K., Pezzella, F., and Pastorino, U. (2004) Lung cancers detected by screening with spiral computed tomography have a malignant phenotype when analyzed by cDNA microarray. Clin. Cancer Res. 10, 6023-6028
61. Yasunaga, J., Taniguchi, Y., Nosaka, K., Yoshida, M., Satou, Y., Sakai, T., Mitsuya, H., and Matsuoka, M. (2004) Identification of aberrantly methylated genes in association with adult T-cell leukemia. Cancer Res. 64, 6002-6009
62. Wang, J., Place, R. F., Huang, V., Wang, X., Noonan, E. J., Magyar, C. E., Huang, J., and Li, L.-C. (2010) Prognostic value and function of KLF4 in prostate cancer: RNAa and vector-mediated overexpression identify KLF4 as an inhibitor of tumor cell growth and migration. Cancer Res. 70, 10182-10191
63. Foster, K. W., Frost, A. R., McKie-Bell, P., Lin, C. Y., Engler, J. A., Grizzle, W. E., and Ruppert, J. M. (2000) Increase of GKLF messenger RNA and protein expression during progression of breast cancer. Cancer Res. 60, 6488-6495
64. Pandya, A. Y., Talley, L. I., Frost, A. R., Fitzgerald, T. J., Trivedi, V., Chakravarthy, M., Chhieng, D. C., Grizzle, W. E., Engler, J. A., Krontiras, H., Bland, K. I., LoBuglio, A. F., Lobo-Ruppert, S. M., and Ruppert, J. M. (2004) Nuclear localization of KLF4 is associated with an aggressive phenotype in early-stage breast cancer. Clin. Cancer Res. 10, 2709-2719
65. Yu, F., Li, J., Chen, H., Fu, J., Ray, S., Huang, S., Zheng, H., and Ai, W. (2011) Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene 30, 2161-2172
66. Nagata, T., Shimada, Y., Sekine, S., Hori, R., Matsui, K., Okumura, T., Sawada, S., Fukuoka, J., and Tsukada, K. (2012) Prognostic significance of NANOG and KLF4 for breast cancer. Breast Cancer, in press
67. Akaogi, K., Nakajima, Y., Ito, I., Kawasaki, S., Oie, S. H., Murayama, A., Kimura, K., and Yanagisawa, J. (2009) KLF4 suppresses estrogen-dependent breast cancer growth by inhibiting the transcriptional activity of ERα. Oncogene 28, 2894-2902
68. Yancy, H. F., Mason, J. A., Peters, S., Thompson, C. E., 3rd, Littleton, G. K., Jett, M., and Day, A. A. (2007) Metastatic progression and gene expression between breast cancer cell lines from African American and Caucasian women. J. Carcinog. 6, 8-19
69. Miller, K. A., Eklund, E. A., Peddinghaus, M. L., Cao, Z., Fernandes, N., Turk, P. W., Thimmapaya, B., and Weitzman, S. A. (2001) Kruppel-like factor 4 regulates laminin α 3A expression in mammary epithelial cells. J. Biol. Chem. 276, 42863-42868
70. Yori, J. L., Johnson, E., Zhou, G., Jain, M. K., and Keri, R. A. (2010) Kruppellike factor 4 inhibits epithelial-to-mesenchymal transition through regulation of E-cadherin gene expression. J. Biol. Chem. 285, 16854-16863
71. Rowland, B. D., Bernards, R., and Peeper, D. S. (2005) The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat. Cell Biol. 7, 1074-1082
72. Rowland, B. D., and Peeper, D. S. (2006) KLF4, p21 and context-dependent opposing forces in cancer. Nat. Rev. Cancer 6, 11-23